MCID: TST004
MIFTS: 42

Testicular Lymphoma

Categories: Reproductive diseases, Immune diseases, Cancer diseases

Aliases & Classifications for Testicular Lymphoma

MalaCards integrated aliases for Testicular Lymphoma:

Name: Testicular Lymphoma 37 12 14
Malignant Lymphoma of Testis 12 69
Lymphoma of the Testis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12253
NCIt 46 C6810
SNOMED-CT 64 277664004
UMLS 69 C0349644

Summaries for Testicular Lymphoma

MalaCards based summary : Testicular Lymphoma, also known as malignant lymphoma of testis, is related to central nervous system lymphoma and lymphoma. An important gene associated with Testicular Lymphoma is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are NF-kappaB Signaling and Dendritic Cells Developmental Lineage Pathway. The drugs rituximab and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include testis, b cells and bone, and related phenotypes are homeostasis/metabolism and liver/biliary system

Related Diseases for Testicular Lymphoma

Diseases related to Testicular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
# Related Disease Score Top Affiliating Genes
1 central nervous system lymphoma 29.2 BCL6 FOXP1 MYD88
2 lymphoma 10.6
3 primary central nervous system lymphoma 10.2 BCL6 MYD88
4 gallbladder lymphoma 10.2 BCL6 MME
5 primary mediastinal large b-cell lymphoma 10.1 BCL6 FOXP1
6 intravascular large b-cell lymphoma 10.1 BCL6 MME
7 angioimmunoblastic t-cell lymphoma 10.1 BCL6 MME
8 t-cell/histiocyte rich large b cell lymphoma 10.1 BCL6 MME
9 nodular lymphocyte predominant hodgkin lymphoma 10.1 BCL6 PTPRC
10 colon lymphoma 10.0 BCL6 PTPRC
11 plasmablastic lymphoma 10.0 BCL6 PTPRC
12 gamma heavy chain disease 10.0 MYD88 PTPRC
13 epidural neoplasm 10.0 BCL6 PTPRC
14 ovarian lymphoma 10.0 MME PTPRC
15 lymphosarcoma 10.0 BCL6 PTPRC
16 lymphatic system cancer 9.9 BCL6 PTPRC
17 reticulosarcoma 9.9 BCL6 PTPRC
18 marginal zone b-cell lymphoma 9.9 BCL6 MME MYD88
19 leukemia, acute lymphoblastic 3 9.9 FOXP1 MME
20 lymphoma, hodgkin, classic 9.8 BCL6 PTPRC
21 follicular lymphoma 9.8 BCL6 MME
22 lymphoma, mucosa-associated lymphoid type 9.8 BCL6 FOXP1 MME
23 b-cell lymphomas 9.8 BCL6 FOXP1 MME
24 prostatitis 9.7
25 heart lymphoma 9.7 BCL6 MME PTPRC
26 mature b-cell neoplasm 9.7 BCL6 MME PTPRC
27 lymphoblastic lymphoma 9.7 BCL6 MME PTPRC
28 mantle cell lymphoma 9.7 BCL6 MME
29 lymphoma, non-hodgkin, familial 9.6 BCL6 MME PTPRC
30 myasthenia gravis 9.6
31 retinitis pigmentosa and erythrocytic microcytosis 9.6
32 intraocular lymphoma 9.6
33 multiple cranial nerve palsy 9.6
34 cranial nerve palsy 9.6
35 pancreatitis 9.6
36 acquired immunodeficiency syndrome 9.6
37 hydrocele 9.6
38 myasthenia gravis congenital 9.6
39 diffuse large b-cell lymphoma 9.5 BCL6 FOXP1 MME MYD88

Graphical network of the top 20 diseases related to Testicular Lymphoma:



Diseases related to Testicular Lymphoma

Symptoms & Phenotypes for Testicular Lymphoma

MGI Mouse Phenotypes related to Testicular Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.43 BCL6 MME MYD88 PNLIP POLK PTPRC
2 liver/biliary system MP:0005370 8.92 BCL6 MME PNLIP PTPRC

Drugs & Therapeutics for Testicular Lymphoma

Drugs for Testicular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
2
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
3
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
4
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
5
Vorinostat Approved, Investigational Phase 2,Phase 1 149647-78-9 5311
6
Busulfan Approved, Investigational Phase 2,Early Phase 1 55-98-1 2478
7
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
8
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
9
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
10
Iron Approved Phase 2 7439-89-6 23925
11
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
13
alemtuzumab Approved, Investigational Phase 2 216503-57-0
14
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
15
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
16
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 21704 32326
17
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
18
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
19
Gemcitabine Approved Phase 2 95058-81-4 60750
20
Etoposide Approved Phase 1, Phase 2,Early Phase 1 33419-42-0 36462
21
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
22
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
23
nivolumab Approved Phase 2 946414-94-4
24
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
25
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
26
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
27
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
28 Thiotepa Approved, Investigational Phase 2 52-24-4 5453
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
30
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
31
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
32
Doxil Approved June 1999 Phase 2,Phase 1 31703
33 Antibodies Phase 1, Phase 2
34 Antibodies, Monoclonal Phase 1, Phase 2
35 Antirheumatic Agents Phase 1, Phase 2, Early Phase 1
36 Immunoglobulins Phase 1, Phase 2
37 Antifungal Agents Phase 2,Phase 1
38 Anti-Infective Agents Phase 2,Phase 1
39 Antimetabolites Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 2,Phase 1
41 Calcineurin Inhibitors Phase 2,Phase 1
42 Cyclosporins Phase 2,Phase 1
43 Dermatologic Agents Phase 2,Phase 1
44 Folic Acid Antagonists Phase 2
45 Histone Deacetylase Inhibitors Phase 2,Phase 1
46 Immunosuppressive Agents Phase 2,Phase 1,Early Phase 1
47 Nucleic Acid Synthesis Inhibitors Phase 2
48 Vitamin B Complex Phase 2
49 Alkylating Agents Phase 2,Phase 1,Early Phase 1
50 Vidarabine Phosphate Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 51)

# Name Status NCT ID Phase Drugs
1 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
3 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
4 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
5 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
6 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
7 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
8 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
9 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
10 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
11 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
12 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
13 A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) Recruiting NCT02857426 Phase 2 Nivolumab
14 Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis Recruiting NCT00945724 Phase 2 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
15 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
16 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
17 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
18 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
19 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01839916 Phase 2
20 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
21 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
22 Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL Not yet recruiting NCT03212807 Phase 2 Durvalumab;Lenalidomide
23 Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Terminated NCT01769222 Phase 1, Phase 2
24 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Terminated NCT01419795 Phase 2 lenalidomide
25 MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma Terminated NCT00089076 Phase 1, Phase 2
26 Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma Terminated NCT00088881 Phase 2 prednisone;cyclophosphamide;doxorubicin;vincristine
27 Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Withdrawn NCT02281279 Phase 1, Phase 2 lenalidomide;romidepsin
28 Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
29 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Completed NCT01748721 Phase 1
30 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01658319 Phase 1 fludarabine phosphate;methoxyamine
31 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Completed NCT01254578 Phase 1 Lenalidomide
32 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
33 Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Completed NCT00720135 Phase 1
34 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Completed NCT00608361 Phase 1 Dasatinib
35 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma Completed NCT00458731 Phase 1 cediranib maleate
36 Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Recruiting NCT01366144 Phase 1 Carboplatin;Paclitaxel;Veliparib
37 Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma Active, not recruiting NCT01815749 Phase 1
38 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Active, not recruiting NCT01678443 Phase 1
39 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Active, not recruiting NCT01567709 Phase 1 Alisertib;Vorinostat
40 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Active, not recruiting NCT01129193 Phase 1 AR-42
41 CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Terminated NCT02168907 Phase 1 6,8-bis(benzylthio)octanoic acid;bendamustine hydrochloride
42 Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Terminated NCT02109224 Phase 1 Ibrutinib
43 Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Terminated NCT01116154 Phase 1 lenalidomide;vorinostat
44 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant Completed NCT01959477 Early Phase 1 busulfan;etoposide;cyclophosphamide
45 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed NCT00112593 fludarabine phosphate;cyclosporine;mycophenolate mofetil
46 Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas Recruiting NCT01793233
47 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors Active, not recruiting NCT00536601 etoposide;cyclophosphamide;carmustine;melphalan;busulfan;carboplatin;thiotepa
48 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma Active, not recruiting NCT00003196 chemotherapy;cyclosporine;mycophenolate mofetil
49 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Active, not recruiting NCT00014235 fludarabine phosphate;cyclosporine;mycophenolate mofetil
50 Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma Terminated NCT01408043 plerixafor;etoposide

Search NIH Clinical Center for Testicular Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Testicular Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Testicular Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Testicular Lymphoma:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Testicular Lymphoma

Anatomical Context for Testicular Lymphoma

MalaCards organs/tissues related to Testicular Lymphoma:

38
Testis, B Cells, Bone, Bone Marrow, T Cells, Liver, Kidney

Publications for Testicular Lymphoma

Articles related to Testicular Lymphoma:

(show top 50) (show all 94)
# Title Authors Year
1
Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution. ( 28612278 )
2017
2
Bilateral hydrocele. Uncommon clinical presentation of primary testicular lymphoma in the elderly. ( 28383626 )
2017
3
"The moon on the water": a characteristic ultrasonographic appearance of testicular lymphoma. ( 29135132 )
2017
4
High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with cardiac involvement. ( 28883219 )
2017
5
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. ( 28356247 )
2017
6
Straight Vessel Pattern and Rapid Filling Time: Characteristic Findings on Contrast-Enhanced Sonography of Testicular Lymphoma. ( 27335443 )
2016
7
Primary testicular lymphoma: Two case reports and review of the literature. ( 26766810 )
2015
8
Isolated Central Nervous System Relapse After 10A Years in a Case of Primary Testicular Lymphoma Detected on (18)F-FDG PET/CT. ( 26550055 )
2015
9
Primary testicular lymphoma. ( 25444963 )
2015
10
Primary testicular lymphoma with solitary cutaneous nodule as the initial presentation. ( 26664513 )
2015
11
Unusual continuous intra-abdominal spread of primary testicular lymphoma along the spermatic cord and gonadal vessels: Report of 2 cases. ( 26649126 )
2015
12
High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses. ( 26388135 )
2015
13
Primary testicular lymphoma. ( 26433344 )
2015
14
Various neurological symptoms by neurolymphomatosis as the initial presentation of primary testicular lymphoma. ( 26034480 )
2015
15
Grayscale and color Doppler features of testicular lymphoma. ( 26014335 )
2015
16
Recurrent genomic rearrangements in primary testicular lymphoma. ( 25712539 )
2015
17
Primary testicular lymphoma: a single centre experience. ( 26422109 )
2015
18
Single-center experience in the treatment of primary testicular lymphoma. ( 24853782 )
2014
19
Primary testicular lymphoma with subcutaneous masses as the sole manifestation of the first relapse and central nervous system lymphoma as the second relapse: A case report and literature review. ( 24932252 )
2014
20
Bilateral primary testicular lymphoma. ( 24692378 )
2014
21
Primary testicular lymphoma. ( 24282217 )
2014
22
Scrotal irradiation in primary testicular lymphoma: review of the literature and in silico planning comparative study. ( 22836054 )
2013
23
Primary testicular lymphoma with rupture: An unusual presentation. ( 23633871 )
2013
24
Three prognostic factors influence clinical outcomes of primary testicular lymphoma. ( 22965883 )
2013
25
Huge testicular lymphoma on 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography-computed tomography. ( 23187303 )
2013
26
Clinical Features of Testicular Lymphoma. ( 24247653 )
2013
27
Primary testicular lymphoma: experience with 13 cases and literature review. ( 23355262 )
2013
28
Testicular lymphoma. ( 23945480 )
2013
29
Intraocular (vitreoretinal) lymphoma following primary testicular lymphoma. ( 23931497 )
2013
30
Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. ( 23680437 )
2013
31
F18 FDG positron emission tomography revelation of primary testicular lymphoma with concurrent multiple extra nodal involvement. ( 24019676 )
2013
32
FDG PET/CT of bilateral testicular lymphoma. ( 22157041 )
2012
33
Primary testicular lymphoma. ( 22424983 )
2012
34
Primary testicular lymphoma with cardiac involvement in an immunocompetent patient: case report and a concise review of literature. ( 23087799 )
2012
35
Primary diffuse large B-cell testicular lymphoma: magnetic resonance imaging findings. ( 21988565 )
2012
36
Relapsed testicular lymphoma presenting with cranial nerve neurolymphomatosis. ( 21502608 )
2011
37
Clinics in diagnostic imaging (134). Testicular lymphoma. ( 21451930 )
2011
38
Testicular lymphoma, intraocular (vitreoretinal) lymphoma, and brain lymphoma: involvement of three immunoprivileged sites in one patient. ( 20658596 )
2010
39
Primary testicular lymphoma. ( 20872294 )
2010
40
Testicular lymphoma. ( 21167372 )
2010
41
Primary testicular lymphoma: a strictly homogeneous hematological disease? ( 20372839 )
2010
42
Primary testicular lymphoma: the site matters. ( 20497004 )
2010
43
Primary testicular lymphoma involving the spermatic cord and gonadal vein. ( 19300051 )
2009
44
Primary testicular lymphoma with extranodal involvement. ( 19736380 )
2009
45
Rituximab and dose-dense chemotherapy in primary testicular lymphoma. ( 19858059 )
2009
46
Primary testicular lymphoma. ( 17962036 )
2008
47
Intraocular lymphoma following a primary testicular lymphoma in remission for 10 years. ( 17985076 )
2008
48
Testicular lymphoma: an update for clinicians. ( 18854677 )
2008
49
Primary testicular lymphoma. ( 17945289 )
2007
50
Consideration of aggressive therapeutic strategies for primary testicular lymphoma. ( 17563078 )
2007

Variations for Testicular Lymphoma

Expression for Testicular Lymphoma

Search GEO for disease gene expression data for Testicular Lymphoma.

Pathways for Testicular Lymphoma

Pathways related to Testicular Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 BCL6 MYD88 PTPRC
2 11.13 MME PTPRC
3 10.52 BCL6 MME PTPRC
4 10.46 MME PTPRC

GO Terms for Testicular Lymphoma

Cellular components related to Testicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule membrane GO:0030667 8.62 MME PTPRC

Biological processes related to Testicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of smooth muscle cell proliferation GO:0048661 9.32 FOXP1 MYD88
2 positive regulation of B cell proliferation GO:0030890 9.26 BCL6 PTPRC
3 negative regulation of B cell apoptotic process GO:0002903 9.16 BCL6 FOXP1
4 regulation of tumor necrosis factor production GO:0032680 8.96 FOXP1 MYD88
5 regulation of inflammatory response GO:0050727 8.8 BCL6 FOXP1 MYD88

Molecular functions related to Testicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein self-association GO:0043621 8.62 FOXP1 MYD88

Sources for Testicular Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....